About this episode
Join Professor Hideto Kameda, and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. Our first paper aimed to use mediation modelling to determine whether tofacitinib improved fatigue symptoms directly or indirectly. Our second paper shows that IV-golimumab reduces fatigue symptoms in patients with ankylosing spondylitis.
Get every episode summarized
Each time The IMID Forum publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The IMID Forum
Discussing PsA: Bimekizumab in PsA: Clinical efficacy and updated safety profile
The IMID Forum
Apr 14, 202616:32failed
Author Interview: Professor Helena Marzo-Ortega, March 2026
The IMID Forum
Apr 9, 202637:39failed
Discussing RA: Malignancy risk in patients with RA and the evolution of JAKi pre...
The IMID Forum
Mar 26, 202610:02failed
Discussing axSpA: Symptom duration impact on bimekizumab efficacy and therapeuti...
The IMID Forum
Mar 19, 202633:29failed